ImmunityBio: ImmunityBio announces US FDA submissions of sBLA for NMIBC papillary disease and EAP for Anktiva to treat lymphopenia

ImmunityBio, Inc, a leading immunotherapy company, announced that it has completed multiple submissions to the US FDA including an sBLA for BCG─unresponsive NMIBC in papillary disease and an EAP for